Advancing New Hope for KCNT1-Related Epilepsy
Welcome
This site is for families and caregivers exploring a new clinical trial for ABS-1230, an investigational treatment for KCNT1-related epilepsy – a rare and severe genetic epilepsy that begins in early life.
ABS-1230 is an investigational medicine that is designed to target the KCNT1 ion channel overactivity in the brain, with the goal of reducing seizures and improving quality of life, regardless of a person’s specific KCNT1 mutation.
This Phase 1b/2 clinical trial is now enrolling in the U.S. Explore this site to learn more, view key eligibility, and see if this trial may be right for your family.
Could This Study Be Right for Your Family?
Answer a few quick questions to help us understand if your child might be eligible for the ABS-1230 clinical trial for KCNT1-related epilepsy.
This is not a formal enrollment form.
Your responses are confidential and will help our team connect you with more information.